Accessibility Menu
Daiichi Sankyo, logo

Daiichi Sankyo,(OTC) DSKYF

Market Cap$31.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)+140%
5 Year+4%
1 Year-26%
1 Month+5%
$18.07
+2.96%
+0.52Today
Daiichi Sankyo, last closing stock price
MetricPriceDate
Last closeUSD 17.552026-08-06
Daiichi Sankyo, stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.72%USD 16.602026-07-30
1 month+5.09%USD 16.702026-07-07
3 month+2.66%USD 17.102026-05-08
Year to date-17.27%USD 21.212025-12-31
1 year-26.09%USD 23.742025-08-06
3 year-39.33%USD 28.932023-08-07
5 year+3.78%USD 16.912021-08-06
Since inception+139.7%USD 6.662006-02-28

Daiichi Sankyo, Financials at a Glance

Market Cap

$31.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥2.23T

Net Income (TTM)

¥243.51B

EPS (TTM)

$0.85

P/E Ratio

20.56

Dividend

$0.51

Beta (Volatility)

0.34 (Low)

Price

$18.07

Volume

2,013

Open

$16.01

Previous Close

$17.55

Daily Range

$15.91 - $18.63

52-Week Range

$13.85 - $29.15

Estimated Earnings Date

Nov 4, 2026

DSKYF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Daiichi Sankyo,

Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products. The company boasts an extensive portfolio of therapeutics spanning numerous health conditions.

Products and Services
  • Innovative oncology treatments, including trastuzumab deruxtecan
  • Medications for chronic diseases like diabetes and hypercholesterolemia
  • Consumer health products and vaccines for various diseases
Growth Outlook
  • Recent quarterly revenue reached JPY 593.3 billion, showing strong demand
  • Net income for Q4 was JPY 42.7 billion, indicating profitability
  • Continued investment in R&D, with JPY 127 billion allocated last quarter
Financial Highlights
  • Trailing twelve months (TTM) revenue of JPY 2.3 trillion
  • Net profit margin of 12.24%, reflecting operational efficiency
  • Dividend yield of 3.04%, providing attractive returns to shareholders
Daiichi Sankyo Company, Limited is well-positioned in the pharmaceutical industry, with a diverse product portfolio that addresses critical health issues. The company's commitment to research and development is evident in its substantial investment, which supports innovation and growth. Recent financial performance highlights a robust revenue stream and profitability, making it an intriguing option for potential investors. The company's focus on oncology and chronic disease treatments aligns with global health trends, further enhancing its growth prospects. With a solid dividend yield, Daiichi Sankyo presents an appealing opportunity for those interested in the healthcare sector.
AI Generated • Aug 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

20,171

CEO

Hiroyuki Okuzawa

Website

www.daiichisankyo.co.jp

Headquarters

Tokyo, TY 103-8426, JP

DSKYF Financials

Key Financial Metrics (TTM)

Gross Margin

68.47%

Operating Margin

8.83%

Net Income Margin

10.93%

Return on Equity

14.44%

Return on Capital

10.55%

Return on Assets

5.91%

Earnings Yield

4.86%

Dividend Yield

2.90%

Payout Ratio

59.07%

Stock Overview

Market Cap

$31.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.82B

Volume

2.01K

Avg. Volume

12.96K

Financials (TTM)

Gross Profit

¥1.53T

Operating Income

¥196.34B

EBITDA

¥311.33B

Operating Cash Flow

¥134.76B

Capital Expenditure

-¥137.38B

Free Cash Flow

-¥2.62B

Cash & ST Invst.

¥633.24B

Total Debt

¥496.86B

Daiichi Sankyo, Performance Analysis

Daiichi Sankyo, annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 9,437,849,0681.5%
20242024-03-31JPY 11,090,991,16917.5%
20252025-03-31JPY 12,372,918,73811.6%
20262026-03-31JPY 14,088,629,81013.9%
Daiichi Sankyo, sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-307.0%
Q32025-12-3110.0%
Q42026-03-316.2%
Q12026-06-30-3.8%
Daiichi Sankyo, annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.4235.2%
20242024-03-31JPY 0.7272.5%
20252025-03-31JPY 1.0241.1%
20262026-03-31JPY 0.93-8.9%
Daiichi Sankyo, sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-46.0%
Q32025-12-3188.5%
Q42026-03-31-48.8%
Q12026-06-3054.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥570.58B

+20.2%

Gross Profit

¥447.19B

+17.0%

Gross Margin

78.37%

N/A

Market Cap

$31.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.58M

N/A

Employees

20,171

N/A

Net Income

¥68.14B

-20.3%

EBITDA

¥105.75B

-7.7%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥633.24B

+10.3%

Total Debt

¥496.86B

+146.9%

Accounts Receivable

¥672.03B

+9.9%

Inventory

¥727.75B

+29.0%

Long Term Debt

¥496.39B

+392.3%

Short Term Debt

¥474.54M

-99.5%

Return on Assets

5.91%

N/A

Return on Invested Capital

5.86%

N/A

Free Cash Flow

-¥16.78B

+74.3%

Operating Cash Flow

¥20.18B

+155.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OTSKYOtsuka Holdings Co., Ltd.
$40.58+5.57%
HLNCFHaleon plc
$4.99+2.57%
UCBJYUCB S.A.
$130.80+1.13%
UCBJFUCB S.A.
$269.84+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$125.07+0.09%
TTDThe Trade Desk
$14.16-0.20%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.50+0.02%
INTCIntel
$99.69-0.00%

Questions About DSKYF

What is the current price of Daiichi Sankyo,?

Daiichi Sankyo, is trading at $18.07 per share.

What is the 52-week range for Daiichi Sankyo,?

Over the past 52 weeks, Daiichi Sankyo, has traded between $13.85 and $29.15.

How much debt does Daiichi Sankyo, have?

As of the most recent reporting period, Daiichi Sankyo, reported total debt of ¥3.08B.

How much cash does Daiichi Sankyo, have on hand?

Daiichi Sankyo, reported ¥3.92B in cash and cash equivalents in its most recent financial results.

What is Daiichi Sankyo,’s dividend yield?

Daiichi Sankyo, currently has a dividend yield of 2.90%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services